These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12120260)

  • 21. Pharmacogenetics initiative galvanizes public and private sectors.
    Smaglik P
    Nat Biotechnol; 2001 Jul; 19(7):691-2. PubMed ID: 11433290
    [No Abstract]   [Full Text] [Related]  

  • 22. Pharmacogenomics of antidepressant drugs.
    Horstmann S; Binder EB
    Pharmacol Ther; 2009 Oct; 124(1):57-73. PubMed ID: 19563827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacogenetics for individualized cancer chemotherapy.
    Efferth T; Volm M
    Pharmacol Ther; 2005 Aug; 107(2):155-76. PubMed ID: 15890408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pharmacogenetic-assisted drug development. Regulatory aspects from the viewpoint of the Medical Products Agency].
    Theilade MD
    Ugeskr Laeger; 2005 May; 167(20):2146-50. PubMed ID: 15987069
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers.
    Grossman I; Avidan N; Singer C; Goldstaub D; Hayardeny L; Eyal E; Ben-Asher E; Paperna T; Pe'er I; Lancet D; Beckmann JS; Miller A
    Pharmacogenet Genomics; 2007 Aug; 17(8):657-66. PubMed ID: 17622942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacogenetics of disease-modifying anti-rheumatic drugs.
    Tanaka E; Taniguchi A; Urano W; Yamanaka H; Kamatani N
    Best Pract Res Clin Rheumatol; 2004 Apr; 18(2):233-47. PubMed ID: 15121042
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequential genome-wide association studies for monitoring adverse events in the clinical evaluation of new drugs.
    Kelly P; Stallard N; Zhou Y; Whitehead J; Bowman C
    Stat Med; 2006 Sep; 25(18):3081-92. PubMed ID: 16397864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene polymorphisms involved in triptans pharmacokinetics and pharmacodynamics in migraine therapy.
    Gentile G; Borro M; Simmaco M; Missori S; Lala N; Martelletti P
    Expert Opin Drug Metab Toxicol; 2011 Jan; 7(1):39-47. PubMed ID: 21142809
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene-based SNP discovery as part of the Japanese Millennium Genome Project: identification of 190,562 genetic variations in the human genome. Single-nucleotide polymorphism.
    Haga H; Yamada R; Ohnishi Y; Nakamura Y; Tanaka T
    J Hum Genet; 2002; 47(11):605-10. PubMed ID: 12436197
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacogenetic mechanisms underlying unanticipated drug responses.
    Carlquist JF; Anderson JL
    Discov Med; 2011 May; 11(60):469-78. PubMed ID: 21616045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of single-nucleotide polymorphism maps in pharmacogenomics.
    McCarthy JJ; Hilfiker R
    Nat Biotechnol; 2000 May; 18(5):505-8. PubMed ID: 10802616
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of the human genome on the discovery of immune-modulatory therapeutics.
    Manning AM
    Curr Opin Investig Drugs; 2006 May; 7(5):406-11. PubMed ID: 16729715
    [No Abstract]   [Full Text] [Related]  

  • 33. Biomarker as a classifier in pharmacogenomics clinical trials: a tribute to 30th anniversary of PSI.
    Wang SJ
    Pharm Stat; 2007; 6(4):283-96. PubMed ID: 17957727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rubicon Genomics, Inc.
    Langmore JP
    Pharmacogenomics; 2002 Jul; 3(4):557-60. PubMed ID: 12164778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacogenetics and the concept of individualized medicine.
    Shastry BS
    Pharmacogenomics J; 2006; 6(1):16-21. PubMed ID: 16302022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity?
    Nolan D; Gaudieri S; Mallal S
    J HIV Ther; 2003 May; 8(2):36-41. PubMed ID: 12838163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Applications of pharmacogenetics to drug development: the Glaxo Wellcome experience.
    Arledge T; Freeman A; Arbuckle J; Mosteller M; Manasco P
    Drug Metab Rev; 2000; 32(3-4):387-94. PubMed ID: 11139136
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An SNP map of human chromosome 22.
    Mullikin JC; Hunt SE; Cole CG; Mortimore BJ; Rice CM; Burton J; Matthews LH; Pavitt R; Plumb RW; Sims SK; Ainscough RM; Attwood J; Bailey JM; Barlow K; Bruskiewich RM; Butcher PN; Carter NP; Chen Y; Clee CM; Coggill PC; Davies J; Davies RM; Dawson E; Francis MD; Joy AA; Lamble RG; Langford CF; Macarthy J; Mall V; Moreland A; Overton-Larty EK; Ross MT; Smith LC; Steward CA; Sulston JE; Tinsley EJ; Turney KJ; Willey DL; Wilson GD; McMurray AA; Dunham I; Rogers J; Bentley DR
    Nature; 2000 Sep; 407(6803):516-20. PubMed ID: 11029003
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The prospect of application of toxicogenetics/pharmcogenetics theory and methods in forensic practice].
    Shen DN; Yi XF; Chen XG; Xu TL; Cui LJ
    Fa Yi Xue Za Zhi; 2007 Oct; 23(5):362-4. PubMed ID: 18175577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Using pharmacogene polymorphism panels to detect germline pharmacodynamic markers in oncology.
    Hertz DL; McLeod HL
    Clin Cancer Res; 2014 May; 20(10):2530-40. PubMed ID: 24831276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.